Albireo to participate in guggenheim nantucket therapeutics conference

Boston, sept. 20, 2022 (globe newswire) -- albireo pharma, inc. (nasdaq: albo), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in the guggenheim therapeutics conference in nantucket, ma, from september 27-29, 2022. ron cooper, president and chief executive officer of albireo, will be presenting on september 28, 2022, at 8:30 am et.
ALBO Ratings Summary
ALBO Quant Ranking